Dr Reddy’s Laboratories has come into focus after launching its semaglutide-based injection, Obeda, for the management of type 2 diabetes.
The move marks the company’s entry into the GLP-1 therapy segment, reflecting its strategy to expand access to advanced metabolic treatments.
Obeda is a once-weekly injectable therapy offered in 2 mg and 4 mg strengths, delivered through a pre-filled disposable pen. Each pen provides at least four weekly doses, with the treatment priced at approximately ₹4,200 per month.
The therapy was evaluated in a Phase III clinical study involving 312 participants, where it demonstrated efficacy and safety comparable to the reference drug.
The study showed similar outcomes in glycaemic control, including fasting and post-meal glucose reduction and HbA1c levels below 7%. No anti-drug antibodies were detected, and the safety profile remained consistent with established therapies.
A separate usability study involving 41 participants completing around 20 tasks confirmed that the injection device performs on par with existing alternatives. Semaglutide also has a proven global track record in improving blood sugar control and supporting weight management.
The development of Obeda, including API production, formulation and manufacturing, has been carried out entirely in-house, highlighting the company’s expertise in peptide science and complex drug development.
The launch represents a Day-1 entry into the GLP-1 segment, positioning the company to serve unmet patient needs in India.
The company plans to expand its semaglutide portfolio across international markets and continue building a comprehensive GLP-1 pipeline targeting multiple metabolic conditions.
To enhance patient outcomes, Dr Reddy’s has introduced SemaKare, a support programme that includes digital onboarding, counselling, injection training, tele-support and adherence tracking.
The company is also working on establishing metabolic centres of excellence across India to strengthen diagnosis, treatment infrastructure, healthcare training and patient awareness. These centres will also include safe disposal systems for used devices.
In addition, through its partnership with Nestle Health Science, the company is offering nutritional products such as Celevida GLP+ and Optifast, aimed at improving nutrient intake and supporting metabolic health.
India presents a significant opportunity, with over 101 million adults living with diabetes, a prevalence rate of 11.4%, and an additional 136 million individuals at risk. Rising obesity levels and increasing demand for advanced therapies are expected to drive growth in this segment.
Read More: Natco Pharma Launches Affordable Generic Semaglutide Injection for Type 2 Diabetes in India!
As of 23 March 2026, at 9:37 AM, Dr Reddys Laboratories Ltd share price is trading at ₹1,275.80 per share, reflecting a decline of 1.78% from the previous closing price. Over the past month, the stock has declined by 2.42%.
The launch of Obeda strengthens Dr Reddy’s presence in the metabolic therapy space, combining clinical validation, integrated manufacturing and a broader patient support ecosystem, while positioning the company for future growth in India and global markets.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Mar 23, 2026, 10:16 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN